Patents Assigned to NPS Allelix Corporation
-
Publication number: 20040152740Abstract: The present invention relates to compounds of Formula 1: 1Type: ApplicationFiled: September 8, 2003Publication date: August 5, 2004Applicant: NPS Allelix CorporationInventors: Methvin Isaac, Tao Xin, Tomislav Stefanac, Anne O'Brien, Kathleen Da Silva-Turcot, Jalaj Arora, Shawn Maddaford, Abdelmalik Slassi
-
Publication number: 20040152741Abstract: The present invention relates to compounds of Formula 1, 1Type: ApplicationFiled: September 8, 2003Publication date: August 5, 2004Applicant: NPS Allelix CorporationInventors: Methvin Isaac, Tao Xin, Louise Edwards, Leah Begleiter, Tomislav Stefanac, Anne O'Brien, Kathleen Da Silva-Turcot, Jalaj Arora, Shawn Maddaford, Abdelmalik Slassi
-
Publication number: 20030207809Abstract: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating the large intestine in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the large intestine, including inflammatory bowel diseases.Type: ApplicationFiled: April 21, 2003Publication date: November 6, 2003Applicant: NPS ALLELIX CORPORATIONInventor: Daniel J. Drucker
-
Publication number: 20030162703Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: ApplicationFiled: November 14, 2002Publication date: August 28, 2003Applicant: NPS Allelix CorporationInventors: Daniel J. Drucker, Anna E. Crivici, Martin Sumner Smith
-
Patent number: 6579987Abstract: Provided, among other things, is a compound of Formula I: wherein: Ar1 and Ar2 are independently selected aryl groups, optionally substituted with up to five substituents independently selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloalkyloxy, heterocycloalkyl, heterocycloalkyloxy, alkanoyl, thioalkyl, aralkyl, aralkyloxy, aryloxyalkyl, aryloxyalkoxy, cycloalkyl-substituted alkyl, cycloalkyloxy-substituted alkyl, cycloalkyl-substituted alkoxy, cycloalkyloxy-substituted alkoxy, heterocycloalkyl-substituted alkyl, heterocycloalkyloxy-substituted alkyl, heterocycloalkyl-substituted alkoxy, heterocycloalkyloxy-substituted alkoxy, thioaryl, aralkylthio, thioaryl-alkyl, aralkylthioalkyl, halo, NO2, CF3, CN, OH, alkylenedioxy, SO2NRR′, NRR′, CO2R (where R and R′ are independently selected from the group consisting of H and alkyl), and a second aryl group, which may be substituted as above; R1 is selected from the group consisting of H and alkyl; R2 is seleType: GrantFiled: December 20, 2002Date of Patent: June 17, 2003Assignee: NPS Allelix CorporationInventors: Ian Egle, Jennifer Frey, Methvin Isaac
-
Publication number: 20030092769Abstract: Provided, among other things, is a compound of Formula I: 1Type: ApplicationFiled: December 20, 2002Publication date: May 15, 2003Applicant: NPS Allelix CorporationInventors: Ian Egle, Jennifer Frey, Methvin Isaac
-
Patent number: 6482609Abstract: A lysolipid receptor, a human EDG-4 receptor, a method of identifying lysolipid receptors involved in inflammatory response and the lysolipid receptors so identified, and a method of identifying ligands which interact with such lysolipid receptors.Type: GrantFiled: July 28, 2000Date of Patent: November 19, 2002Assignee: NPS Allelix CorporationInventors: Donald G. Munroe, Rajender Kamboj, Diana Peters, Fatemch Kooshesh, Tejal B. Vyas, Ashwani K. Gupta
-
Patent number: 6406868Abstract: Described herein are isolated polynucleotides which code for an AMPA-type human CNS receptor, designated the human GluR1B receptor. The receptor is characterized structurally and the construction and use of cell lines expressing the receptor is disclosed.Type: GrantFiled: March 23, 1994Date of Patent: June 18, 2002Assignee: NPS Allelix CorporationInventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
-
Patent number: 6403323Abstract: Described herein are isolated polynucleotides which code for a family of AMPA-type human CNS receptors. The receptors are characterized structurally and the construction and use of cell lines expressing these receptors are disclosed.Type: GrantFiled: June 8, 1994Date of Patent: June 11, 2002Assignee: NPS Allelix CorporationInventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt
-
Patent number: 6391566Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. This neurotransmission has been found to be modulated by certain modulatory proteins. DNA coding for a family of such modulatory proteins has now been isolated and the modulatory proteins have been characterized. Herein described are recombinant cell lines which produce these modulatory proteins as heterologous membrane-bound products. Also described are related aspects of the invention, which are of commercial significance, including the use of cell lines which express the modulatory proteins either homomerically, or hotoromorically in a complex with an NMDA receptor, as a tool for discovery of compounds which affect the function of the modulatory proteins.Type: GrantFiled: June 23, 1994Date of Patent: May 21, 2002Assignee: NPS Allelix CorporationInventors: Robert L. Foldes, Sally-Lin Adams, Rajender Kamboj
-
Patent number: 6333161Abstract: Neurotransmission by excitatory amino acids (EAAs) such as glutamate is mediated via membrane-bound surface receptors. DNA coding for one family of these receptors of the kainate-binding type of EAA receptors, has now been isolated and the receptor protein characterized. Herein described are recombinant cell lines which produce the EAA receptor as a heterologous membrane-bound product. Also described are related aspects of the invention, which are of commercial significance. Included is use of the cell lines as a tool for discovery of compounds which modulate EAA receptor stimulation.Type: GrantFiled: January 6, 1994Date of Patent: December 25, 2001Assignee: NPS Allelix CorporationInventors: Rajender Kamboj, Candace E. Elliott, Stephen L. Nutt